



Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Philippe L. Durette, et al.

Serial No. : 09/086,327 Case 19965Y Art Unit: 1654

Filed : May 28, 1998 Examiner: D. Lukton

For : HETEROCYCLIC AMIDE COMPOUNDS AS
CELL ADHESION INHIBITORS

RECEIVED

APR 06 1999

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

The following citations are being submitted under the provisions of 37 CFR 1.56 and 1.97 in order to comply with the duty of disclosure. Its inclusion herein shall not, however, be construed as an admission that any particular cited reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention.

Applicant submits that the references listed on Form PTO 1449 taken alone or in any reasonable combination neither anticipate nor render obvious the present invention. It is respectfully requested that the Examiner initial and return the enclosed copy of Form PTO-1449 to evidence consideration of the disclosed references.

- I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date appearing below.

MERCK & CO., INC.

By W. Hessey Date 3/31/99

[] the attached information is filed within three months of the filing date of the captioned case.

[] in that this reference is being submitted prior to the mailing of the first Action on the merits, no fee is due.

[] in that this reference is being submitted prior to the Examination of the application, no additional fee is required.

the undersigned certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.


[] the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of the statement.

[] further to Information Disclosure Rule 97(c) applicants authorize payment of the fee set forth under 1.17(p). The fee may be taken from Merck Deposit Account No. 13-2755.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

The Examiner is invited to contact the attorney for applicant at the telephone number provided below if such would advance the prosecution of this application. Applicant respectfully requests early examination and Notice of Allowance.

Respectfully submitted,

By 
MOLLIE M. YANG
Reg. No.32,718
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(908) 594-6343

Date: 3/31/99